Advertisement
This technique restores blood flow more quickly and safely than currentcatheter-directed thrombolysis (CDT) techniques. It provides an importantadjunct to the standard therapy of anti-coagulation alone, which is intendedto prevent future clots but does not break up the existing clot.
Advertisement
Gerard O'Sullivan, MD, Interventional Radiologist from University Hospitalin Galway, Ireland, reported the latest outcomes from the manufacturer'sregistry of clinical results of the Trellis catheter at over 360 hospitals inthe U.S. and internationally.
In a total of 827 limbs treated in 771 patients, Grade II and III lysiswith restoration of patency in patients with acute clot was achieved in 97% ofcases. The vast majority of cases (> 80%) were completed in less than twohours in the single-setting of the interventional suite, and the usage of theTrellis catheter itself was typically around 20 minutes. Although requiredwith CDT procedures, no follow-up monitoring in a costly critical care unitwas typically needed with the Trellis catheter treatment.
There were no reported bleeding complications from the Trellis procedurein acute follow up and compared to CDT the dosage of thrombolytic drugs suchas t-PA are appreciably reduced with use of the Trellis device.
"The single biggest change in treating DVT patients with the Trelliscatheter is our ability to get the clot out and have the patients able to walkaway immediately after the procedure," said Dr. O'Sullivan. "Literally, thepatient comes into the procedure with difficulty or cannot walk and I can nowwalk them out of the procedure room at the end of the treatment. Thesepatients are typically back to work in 2-3 days versus the 6-8 weeks withanticoagulation-only treatment."
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device companydedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty,a noted inventor and cardiovascular surgeon, founded the company with thevision of transforming blood clot removal from peripheral blood vessels into afast, simple, minimally-invasive catheter-based procedure. Thousands ofpatients suffering from DVT and other occlusive vascular diseases have beentreated worldwide to date using the company's Trellis(R) Peripheral InfusionSystem and other products.
For more information, visit http://www.bacchusvascular.com
SOURCE Bacchus Vascular, Inc.
